Syncom Formulations (India) Ltd. is a key player in the pharmaceutical sector, known for its innovative products and cost-effective solutions. With a current share price of ₹20.12, the company holds promise for future growth. Here’s an in-depth analysis of its share price predictions from 2024 to 2040.
About Syncom Formulations
Syncom Formulations is an Indian pharmaceutical company specializing in manufacturing and marketing formulations across various therapeutic segments. It serves both domestic and international markets, focusing on affordability and quality.
Company Details
Founded: 1988
Headquarters: Indore, Madhya Pradesh, India
Sector: Pharmaceuticals
Products: Tablets, Capsules, Syrups, Ointments
Market Reach: India and Exports
Promoter Details
Promoter Name
Holding (%)
Institutional Investors
12.50
Retail & Others
87.50
Syncom Formulations Share Price Target 2024
Growth Factors:
Expanding export markets.
Focus on affordable healthcare products.
Minimum Target: ₹22
Maximum Target: ₹25
Syncom Formulations Share Price Target 2025
Key Drivers:
Increased investment in R&D for new formulations.
Growth in the domestic healthcare sector.
Minimum Target: ₹28
Maximum Target: ₹32
Syncom Formulations Share Price Target 2026 to 2030
Year
Minimum Target (₹)
Maximum Target (₹)
2026
35
40
2027
42
48
2028
50
58
2029
60
72
2030
75
90
Syncom Formulations Share Price Target 2035
Long-Term Catalysts:
Entry into niche therapeutic areas.
Diversification into over-the-counter (OTC) products.
Minimum Target: ₹110
Maximum Target: ₹135
Syncom Formulations Share Price Target 2040
By 2040, Syncom Formulations is expected to leverage its market presence and innovation to achieve robust growth.
Minimum Target: ₹150
Maximum Target: ₹180
Final Thoughts
Syncom Formulations has the potential to grow steadily in the coming years, driven by its focus on affordable medicines and international expansion. However, stock performance depends on market conditions and the company’s execution of its growth plans.
Disclaimer: Stock market investments are subject to risks. Perform thorough research or consult a financial advisor before investing. For more insights, visit moneyphobia.in!
Recent Posts
Dividend, Share Buyback in Q4 results 2026: Double delight by THIS BSE 500 stock; board meeting next week - ET Now
Indian Financial Firms: Results, Dividends Due Amid HDFC Bank Shake-up, Bajaj Acquisition - Whalesbook
Q4 result today: ICICI Prudential, Den Networks among 8 firms on April 14 - Business Standard
Anand Rathi, ICICI Prudential Life Insurance and 5 other stocks announcing Q4 results today - Trade Brains
Patanjali Foods board to meet on April 21 to consider second interim dividend, Q4 earnings - The Economic Times
India Pesticides Corrects XBRL Error in Quarterly Results Filing - TipRanks
Q4 results 2026: Wipro, HDFC Bank, ICICI Bank among 50 companies to declare earnings next week; check full list here - Mint
D-Street week ahead: Q4 earnings, Iran-US talks outcome to drive markets in truncated trading week - The Economic Times
India Cements Announces UltraTech Cement Earnings Call for Q4FY26 Results on April 27, 2026 - scanx.trade
India's TCS falls as rare annual revenue drop dulls quarterly earnings beat, deal wins - Reuters
Indian Stock Bulls Count on Earnings to Extend Best Winning Run Since November - Bloomberg.com
TCS Q4 FY26 results: Tata Consultancy Services reports 12% rise in net profit at Rs 13,718 crore; dividen - The Times of India